Provided by Tiger Trade Technology Pte. Ltd.

Akebia Therapeutics

0.8148
-0.0586-6.71%
Post-market: 0.81510.0003+0.04%17:22 EDT
Volume:7.44M
Turnover:6.17M
Market Cap:225.79M
PE:-7.33
High:0.8664
Open:0.8521
Low:0.8148
Close:0.8734
52wk High:3.20
52wk Low:0.8140
Shares:277.11M
Float Shares:269.24M
Volume Ratio:1.08
T/O Rate:2.77%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1112
EPS(LYR):-0.0208
ROE:-109.38%
ROA:-1.05%
PB:9.02
PE(LYR):-39.20

Loading ...

Akebia says new Vafseo dosing patent is listed in FDA Orange Book

Reuters
·
Jun 10

Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio

GlobeNewswire
·
Jun 10

Akebia Therapeutics grants new hire options for 8,400 shares at $1.02 each

Reuters
·
Jun 02

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 02

Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

GlobeNewswire
·
May 28

Akebia Therapeutics Earnings Call: Vafseo Drives Transition

TIPRANKS
·
May 20

Akebia Therapeutics Balances Vafseo Momentum With Headwinds

TIPRANKS
·
May 09

Akebia Q1 revenue falls, net income misses analyst estimates on higher expenses

Reuters
·
May 07

Akebia Q1 FY26 turns to net loss of $9.1 million; revenue falls to $53.5 million

Reuters
·
May 07

Akebia Therapeutics Q1 EPS $(0.03), Inline, Sales $53.544M Beat $51.668M Estimate

Benzinga Earnings
·
May 07

Akebia Therapeutics Q1 Revenue USD 53.5 Million VS. Ibes Estimate USD 51.7 Million

THOMSON REUTERS
·
May 07

Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights

GlobeNewswire
·
May 07

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 07

Akebia Therapeutics Inc expected to post a loss of 3 cents a share - Earnings Preview

Reuters
·
May 05

Akebia grants new hires options for 208,800 shares at $1.38 each

Reuters
·
May 05

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
May 05

Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology

GlobeNewswire
·
May 04

Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights

GlobeNewswire
·
May 01

Akebia Therapeutics announces annual shareholder meeting via webcast

Reuters
·
Apr 29

Akebia Therapeutics (AKBA) Gets a Buy from Piper Sandler

TIPRANKS
·
Apr 24